The decision prevents Ranbaxy from launching its drug before Lipitor’s basic patent expires in November 2011. Ranbaxy can seek to appeal the decision to the Supreme Court of the Netherlands.
Allen Waxman, general counsel of Pfizer, said: “The court’s ruling reinforces the fundamental principle that patent laws exist to support and encourage medical innovators, not undermine them.”